SAB Biotherapeutics, Inc. (SABSW) 의 후행 P/E는 5.5. 후행 이익수익률은 18.26%. 그레이엄 넘버는 $11.01.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 55/100 2/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2019 | -49.1 | 0.00 | -191.37 | 128.19 | - |
| 2020 | 21.9 | -0.01 | 11.31 | 7.99 | - |
| 2021 | -19.8 | 0.11 | 8.81 | 5.58 | - |
| 2022 | -1.4 | -0.15 | 0.83 | 1.07 | - |
| 2023 | -0.9 | -0.01 | 0.66 | 16.96 | - |
| 2024 | -1.0 | 0.02 | 1.35 | 26.54 | - |
| 2025 | 5.4 | -0.05 | 0.48 | 0.00 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2019 | $-0.22 | $3.44M | $-8.99M | -261.1% |
| 2020 | $7.45 | $55.24M | $20.12M | 36.4% |
| 2021 | $-6.30 | $60.88M | $-17.15M | -28.2% |
| 2022 | $-4.31 | $23.9M | $-18.74M | -78.4% |
| 2023 | $-7.64 | $2.24M | $-42.19M | -1884.5% |
| 2024 | $-3.68 | $1.32M | $-34.11M | -2579.8% |
| 2025 | $-0.79 | $0.00 | $13.27M | - |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $-0.73 | $-0.73 – $-0.73 | $333.33K | $333.33K – $333.33K | 1 |
| 2027 | $-0.45 | $-0.45 – $-0.45 | $83.33K | $83.33K – $83.33K | 1 |
| 2028 | $-0.47 | $-0.47 – $-0.47 | $11.87M | $11.87M – $11.87M | 1 |
| 2029 | $-0.37 | $-0.37 – $-0.37 | $83.38M | $83.38M – $83.38M | 1 |
| 2030 | $-0.03 | $-0.03 – $-0.03 | $218.48M | $218.48M – $218.48M | 1 |
